Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Editor’s Pick: Five Healthcare News Headlines for August 10 - August 23
August 24, 2015
- PMDA Reviewing Opdivo for Risk of Myasthenia Gravis
August 24, 2015
- Novartis’s Equa-Metformin Combination Drug Added to PAFSC 1st Committee’s Review List for Aug. 28
August 24, 2015
- MHLW Designates Carfilzomib as Orphan Drug
August 21, 2015
- Lawmakers Discuss Cost-Effectiveness of Measures to Prevent Cervical Cancer
August 21, 2015
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
- Japan, South Korea Sign MOU for Regulatory Affairs
August 21, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- PMDA, AMED Ink Pact to Spur Commercialization of Novel Drugs
August 20, 2015
- PAFSC’s 2nd Committee to Discuss AbbVie’s Combination Drug for Hepatitis C on Aug. 31
August 19, 2015
- PAFSC 2nd Committee to Discuss Orphan Drug Designation for 3 APIs on Aug. 31
August 19, 2015
- 18 Firms Win Approval for Jzoloft Generics, 25 for Exforge Generics
August 18, 2015
- Govt, Pharma Leaders to Meet on Aug. 24 over “Comprehensive Strategy”
August 18, 2015
- FY2016 Drug Pricing Reform
August 18, 2015
- PAFSC First Committee to Review Glatiramer, Add’l Indication for Xarelto on Aug. 28
August 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for July 21 - August 9
August 10, 2015
- MHLW Notifies of Package Insert Changes for Daklinza, Sunvepra
August 10, 2015
- “Greater Emphasis” Will Need to Be Placed on R&D in Field of Oncology: AMED President
August 7, 2015
- MHLW Calls for Package Insert Revision for Inavir, Relenza
August 7, 2015
- Health Minister Reviewing Ways to Strengthen Guidance to Optimize Ethical Drug Ads: Senior Vice Minister Nagaoka
August 6, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…